KR100660508B1 - 생물학적으로 활성인 비타민ｄ 화합물의 염증성 장질환의예방 및 치료에 있어서의 용도 - Google Patents

생물학적으로 활성인 비타민ｄ 화합물의 염증성 장질환의예방 및 치료에 있어서의 용도 Download PDF

Info

Publication number
KR100660508B1
KR100660508B1 KR1020027008018A KR20027008018A KR100660508B1 KR 100660508 B1 KR100660508 B1 KR 100660508B1 KR 1020027008018 A KR1020027008018 A KR 1020027008018A KR 20027008018 A KR20027008018 A KR 20027008018A KR 100660508 B1 KR100660508 B1 KR 100660508B1
Authority
KR
South Korea
Prior art keywords
biologically active
vitamin
administration
group
active vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027008018A
Other languages
English (en)
Korean (ko)
Other versions
KR20020084075A (ko
Inventor
콜린 이. 헤이예스
페이 이 내숄드
Original Assignee
위스콘신 얼럼나이 리서어치 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위스콘신 얼럼나이 리서어치 화운데이션 filed Critical 위스콘신 얼럼나이 리서어치 화운데이션
Publication of KR20020084075A publication Critical patent/KR20020084075A/ko
Application granted granted Critical
Publication of KR100660508B1 publication Critical patent/KR100660508B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020027008018A 1999-12-21 2000-12-21 생물학적으로 활성인 비타민ｄ 화합물의 염증성 장질환의예방 및 치료에 있어서의 용도 Expired - Fee Related KR100660508B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/469,985 US6358939B1 (en) 1999-12-21 1999-12-21 Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US09/469,985 1999-12-21

Publications (2)

Publication Number Publication Date
KR20020084075A KR20020084075A (ko) 2002-11-04
KR100660508B1 true KR100660508B1 (ko) 2006-12-22

Family

ID=23865828

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027008018A Expired - Fee Related KR100660508B1 (ko) 1999-12-21 2000-12-21 생물학적으로 활성인 비타민ｄ 화합물의 염증성 장질환의예방 및 치료에 있어서의 용도

Country Status (9)

Country Link
US (2) US6358939B1 (enExample)
EP (1) EP1240136A4 (enExample)
JP (1) JP2004502638A (enExample)
KR (1) KR100660508B1 (enExample)
AU (1) AU781113B2 (enExample)
CA (1) CA2395200A1 (enExample)
MX (1) MXPA02006257A (enExample)
NO (1) NO326517B1 (enExample)
WO (1) WO2001046132A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU4510001A (en) * 1999-12-02 2001-06-18 Penn State Research Foundation, The Treatment of inflammatory bowel disease with vitamin d compounds
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU2002902A (en) * 2000-11-14 2002-05-27 Techlab Inc Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP1587906A2 (en) * 2003-01-10 2005-10-26 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
GB0513984D0 (en) * 2005-07-07 2005-08-17 Teva Pharma Dosage form
WO2008103420A1 (en) 2007-02-21 2008-08-28 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
EP2144872A2 (en) * 2007-04-18 2010-01-20 Johns Hopkins University Low calcemic, highly antiproliferative, analogs of calcitriol
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CA2981549A1 (en) 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
AU2010282731C1 (en) 2009-08-14 2016-04-21 Berg Llc Vitamin D3 and analogs thereof for treating alopecia
EP2501705B1 (en) 2009-11-20 2014-08-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US8618095B2 (en) 2010-04-13 2013-12-31 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
US20130064859A1 (en) * 2011-01-28 2013-03-14 Sarkis K. Mazmanian Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
PL2723330T3 (pl) * 2011-08-19 2015-12-31 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Lek kombinowany zawierający środek naczynioskurczowy
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
CA2913543C (en) 2013-05-29 2024-01-09 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
CN105451818A (zh) 2013-06-05 2016-03-30 萨克生物研究学院 治疗涉及cxcl12活性的疾病的维生素d受体激动剂
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
KR102343093B1 (ko) 2015-02-23 2021-12-24 삼성전자주식회사 식기 세척기 및 그 제어방법
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312806A (en) 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US4638043A (en) 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5824313A (en) 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
JP2811353B2 (ja) 1990-07-06 1998-10-15 ゼリア新薬工業株式会社 炎症性腸疾患予防・治療剤
ZA916555B (en) 1990-08-27 1993-04-28 Lilly Co Eli Method of treating inflammatory bowel disease
US5391555A (en) 1991-11-12 1995-02-21 Miles Inc. Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
DE4221961A1 (de) * 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
US5294630A (en) 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
GB9223061D0 (en) 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
ATE163262T1 (de) 1993-04-20 1998-03-15 Hexal Ag Wirkstoffplaster
GB9309422D0 (en) 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
GB9314400D0 (en) 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
GB9315253D0 (en) 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
DE4405545A1 (de) * 1994-02-22 1995-08-31 Dietl Hans Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
DK0717034T3 (da) 1994-12-14 1999-10-18 Duphar Int Res Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser
PT806413E (pt) 1995-01-23 2002-03-28 Chugai Pharmaceutical Co Ltd Derivados de vitamina d3 substituidos na posicao 2
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
US5569680A (en) 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
UA48973C2 (uk) 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
ES2144183T3 (es) 1995-10-30 2000-06-01 Hoffmann La Roche 1-alfa,26-dihidroxi-d-homo-vitamina d3.
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
AU710931B2 (en) 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
GB9607034D0 (en) 1996-04-03 1996-06-05 Leo Pharm Prod Ltd Chemical compounds
ATE227564T1 (de) 1996-04-04 2002-11-15 Cilag Ag Topische vitamin d zusammensetzung auf liposomenbasis
US5891865A (en) 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
JP2002505668A (ja) * 1997-05-16 2002-02-19 ウィメン アンド インファンツ ホスピタル 環状エーテルビタミンＤ３化合物、１α（ＯＨ）３−エピ−ビタミンＤ３化合物及びそれらの使用法
NL1006072C2 (nl) 1997-05-16 1998-11-17 Jacobs Johannes J Vergister voor het onder aërobe omstandigheden vergisten van dierlijke mest, inrichting en werkwijze voor het onder aërobe omstandigheden vergisten van dierlijke mest onder toepassing van een dergelijke vergister.
US6017908A (en) * 1997-05-16 2000-01-25 Women And Infants Hospital 3-EPI vitamin D2 compounds and uses thereof
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
EP0927721A1 (de) * 1997-12-17 1999-07-07 Schering Aktiengesellschaft Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US6214373B1 (en) * 1999-10-07 2001-04-10 Snowden-Sutton Associates, Inc. Nutritional composition for treating inflammatory bowel diseases
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
AU4510001A (en) * 1999-12-02 2001-06-18 Penn State Research Foundation, The Treatment of inflammatory bowel disease with vitamin d compounds
AU7544501A (en) * 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications

Also Published As

Publication number Publication date
EP1240136A4 (en) 2004-05-26
US20020128241A1 (en) 2002-09-12
EP1240136A1 (en) 2002-09-18
WO2001046132A1 (en) 2001-06-28
JP2004502638A (ja) 2004-01-29
AU2287801A (en) 2001-07-03
CA2395200A1 (en) 2001-06-28
NO20022974D0 (no) 2002-06-20
NO326517B1 (no) 2008-12-22
MXPA02006257A (es) 2004-12-06
NO20022974L (no) 2002-08-20
US6858595B2 (en) 2005-02-22
KR20020084075A (ko) 2002-11-04
AU781113B2 (en) 2005-05-05
US6358939B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
KR100660508B1 (ko) 생물학적으로 활성인 비타민ｄ 화합물의 염증성 장질환의예방 및 치료에 있어서의 용도
US6989377B2 (en) Treating vitamin D responsive diseases
Yamamoto et al. Immunological effects of vitamin D and their relations to autoimmunity
Frisard et al. Toll-like receptor 4 modulates skeletal muscle substrate metabolism
Laverny et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease
Mathieu et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice
JP6463714B2 (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
Klein et al. Prenatal stress alters immune function in the offspring of rats
Rosenberg et al. Islet-cell regeneration in the diabetic hamster pancreas with restoration of normoglycaemia can be induced by a local growth factor (s)
Amin et al. Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria
Feng et al. Exclusive enteral nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn's disease
Le Bourgot et al. Perinatal short-chain fructooligosaccharides program intestinal microbiota and improve enteroinsular axis function and inflammatory status in high-fat diet-fed adult pigs
AU746210B2 (en) Histone containing composition to treat rheumatoid arthritis
Stio et al. Interaction among vitamin D3 analogue KH 1060, TNF-α, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients
Goswami et al. 1, 25‐Dihydroxyvitamin D3 and dietary vitamin D reduce inflammation in mice lacking intestinal epithelial cell Rab11a
US20040214803A1 (en) Use of vitamin d3 analogue for the treatment of autoimmune diabetes
WO2009115398A1 (en) Vitamin d compounds for the treatment of biliary diseases
Liu Regulation and role of NADPH oxidase 1 in intestinal inflammation
NZ566029A (en) Vitamin D derivatives for the treatment of type I diabetes
Gillies Role of calcitriol in regulating maternal bone and mineral metabolism during pregnancy, lactation, and post-weaning recovery
Gjessing Postoperative insulin resistance and the metabolic and cellular responses to single-dose preoperative oral carbohydrate supplementation–Experimental studies in pigs
FI3600336T3 (fi) Lyhytketjuisten frukto-oligosakkaridien perinataalinen antaminen epätasapainoiseen ruokavalioon liittyvien aineenvaihduntahäiriöiden ehkäisemiseksi aikuisiässä
Lipińska et al. Total antioxidant capacity of human blood plasma from healthy adults
Wang et al. 920 C-Jun Enhances Intestinal Epithelial Restitution After Wounding by Increasing Phospholipase C-γ1 Gene Transcription and CA2+ Signaling
Sarnowska et al. Mechanisms of neuroprotection in hippocampal organotypic culture

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091216

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091216

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000